@wmasjoshmiller@swasFT@swasftResearch Will continue to be available for routine use pending results and discussion with @swasFT while stocks last. We hope to consider an ongoing service evaluation if supported by @EvadeStudy findings.
It's the last day of @EvadeStudy recruitment! With a predicted recruitment of over 800 participants @swasFT and @swasftResearch have done an amazing job! Still time to use the VAD for your #svt patients and if evidence of benefit we hope the device will continue to be available
Thank you to all those that have contributed to the trial and especially to @swasFT and @swasftResearch staff. Even in the face of a cyber attack you have smashed it!😍
#TeamSWASFT is trialling a new device for our patients with an abnormally fast heart rhythm which could help reduce hospital admissions across the #SouthWest.💚
Read more about the study here ▶️swast.nhs.uk/welcome/latest…
Very exciting final stage of @EvadeStudy where by all 100% @swasFT ambulance station clinicians will have access to the Valsalva Assist Device to treat #SVT. Great work by @swasftResearch, @ExeterCTU and @NIHRSW to reach this stage. Approaching 600 patients treated!
bmjopen.bmj.com/content/bmjope…
Delighted that our EVADE SVT protocol paper has been published open access. Designing a pragmatic study for delivery during normal ambulance care by usual treating @swasFT clinicians has been challenging and rewarding. @swasftResearch@NIHRSW
Dream recruitment continues! Thank you @swasFT and @swasftResearch. What an amazing job.
50% of crews can now use the VAD as standard and we hope this will help you in treating your #SVT patients
@EcgsOnly If stable, the patient could be treated with a modified Valsalva Manoeuvre and if treated by @swasFT would be in the #EVADESVT trial. Half of all ambulance stations in this region now have access to a Valsalva Assist Device (VAD) as standard
As of 1st March, half of all @swasFT ambulance stations now have access to the Valsalva Assist Device (VAD) as the routine device to treat #SVT. If it's in the pouch you can use it! #JustaccesstheValsalvapouch@swasftResearch
Thank you to all the @swasFT stations that are contributing to our trial. Mugs on their way to stations that treated the 1st, 100th, 200th and 300th patients, plus a prize draw each month. Who will get 400th? @swasftResearch. Love to see pics of your mugs
Nearly 300 participants recruited to the EVADE SVT study by @swasFT in just 7 months!Amazing effort! EVADE is designed to see if a simple device can reduce conveyance in SVT. Which station will treat the 300th? @swasftResearch@NIHRSW
@Aidan_Baron@swasFT@swasftResearch A 10% point reduction in hospital conveyance, for which EVADE is powered to detect, would pay for devices for an entire ambulance trust within 7 months. Given the delays ambulances are currently experiencing at EDs there are the wider benefits of avoiding convayance too.
Excited that as of 1st Nov the Valsalva Assist Device (VAD) will become available to @swasFT paramedics for routine treatment of #SVT. In the @EvadeStudy randomly selected stations will have the VAD stocked on ambulances and devices rolled out to all stations over next 18 months
@Aidan_Baron@swasFT@swasftResearch No. The VAD enables a reliable and pressure controlled strain and includes instructions for an evidence based VM, easily available to paramedics who may rarely perform a VM. We shall see if this has any benefits over a syringe - That is the point of trial!